These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31061068)

  • 21. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
    Mesa RA; Kantarjian H; Tefferi A; Dueck A; Levy R; Vaddi K; Erickson-Viitanen S; Thomas DA; Cortes J; Borthakur G; Pardanani AD; Estrov Z; Verstovsek S
    Cancer; 2011 Nov; 117(21):4869-4877. PubMed ID: 21480207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacologic management of myelofibrosis.
    Leung M; Highsmith K; Rexwinkle A
    J Oncol Pharm Pract; 2017 Dec; 23(8):591-601. PubMed ID: 27672139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.
    Massaro F; Molica M; Breccia M
    Expert Rev Hematol; 2017 Feb; 10(2):155-159. PubMed ID: 27983880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets.
    Psaila B; Wang G; Rodriguez-Meira A; Li R; Heuston EF; Murphy L; Yee D; Hitchcock IS; Sousos N; O'Sullivan J; Anderson S; Senis YA; Weinberg OK; Calicchio ML; ; Iskander D; Royston D; Milojkovic D; Roberts I; Bodine DM; Thongjuea S; Mead AJ
    Mol Cell; 2020 May; 78(3):477-492.e8. PubMed ID: 32386542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib.
    Wilkins BS; Radia D; Woodley C; Farhi SE; Keohane C; Harrison CN
    Haematologica; 2013 Dec; 98(12):1872-6. PubMed ID: 24056820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1
    Arciprete F; Verachi P; Martelli F; Valeri M; Balliu M; Guglielmelli P; Vannucchi AM; Migliaccio AR; Zingariello M
    Exp Hematol; 2023 May; 121():30-37. PubMed ID: 36863479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows.
    Zetterberg E; Vannucchi AM; Migliaccio AR; Vainchenker W; Tulliez M; Dickie R; Hasselbalch H; Rogers R; Palmblad J
    Haematologica; 2007 May; 92(5):597-604. PubMed ID: 17488682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of JAK inhibitors for low-risk myelofibrosis.
    Alimam S; McLornan D; Harrison C
    Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
    Del Rosario M; Tsai H; Dasanu CA
    J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing the management of patients with myelofibrosis.
    Manea PJ
    Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors.
    Giraudier S; Chagraoui H; Komura E; Barnache S; Blanchet B; LeCouedic JP; Smith DF; Larbret F; Taksin AL; Moreau-Gachelin F; Casadevall N; Tulliez M; Hulin A; Debili N; Vainchenker W
    Blood; 2002 Oct; 100(8):2932-40. PubMed ID: 12351405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
    Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
    Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
    Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinase signaling and targeted therapy for primary myelofibrosis.
    Yang Q; Crispino JD; Wen QJ
    Exp Hematol; 2017 Apr; 48():32-38. PubMed ID: 28043820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher AURKA and PLK1 expression are associated with inferior overall survival in patients with myelofibrosis.
    Galusic D; Lucijanic M; Livun A; Radman M; Blaslov V; Vicelic Cutura L; Petric M; Miljak A; Lucijanic J; Drmic Hofman I; Kusec R
    Blood Cells Mol Dis; 2020 Mar; 81():102396. PubMed ID: 31837568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.